Abstract
Overview
Introduction
Hypertension is a deadly disease and an important global public health
challenge. Datamonitor estimates that there are currently 192m people with
hypertension in the seven major markets, and this number is set to rise to
212m by 2015. Yet, a significant fraction of this sizeable patient pool
remains undiagnosed or aborts treatment and is thus inaccessible to
antihypertensive pharmacotherapy.
Scope
- Analysis of diagnosis, treatment and blood pressure control rates for the
hypertensive population
- Assessment of the extent to which physicians treat sub-populations
differently
- Examination of the use of combination therapy, drug classes and brands
across the hypertensive sub-populations
- Evaluation of future prescribing trends and the potential of novel
antihypertensive therapies
Report Highlights
There is a significant proportion of patients who drop out of antihypertensive
therapy prematurely. These therapy drop-outs substantially limit market size.
To reduce concomitant loss of potential revenue, drug manufacturers must
sustain aggressive awareness campaigns designed to help patients understand
that hypertension is a deadly disease.
There is space for novel antihypertensive therapies in the hypertension
market. The overwhelming majority of patients are receiving multiple layers of
therapy to control their hypertension, but combination therapy does not sit
well with many patients, as the drugs are costly and often have side effects.
Physicians are generally aware of developmental antihypertensive therapies but
appear reluctant to administer them to their own consulting population.
Reasons to Purchase
- Identify the most lucrative target niche populations for developmental
products
- Understand how to position new antihypertensive therapies
- Gain insight into prescribing patterns and physician opinion on current
treatment paradigms
View Cart
